Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 4
2007 3
2008 3
2009 4
2010 5
2011 10
2012 4
2013 5
2014 9
2015 14
2016 7
2017 10
2018 4
2019 13
2020 8
2021 9
2022 3
Text availability
Article attribute
Article type
Publication date

Search Results

102 results
Results by year
Filters applied: . Clear all
Page 1
Na+ controls hypoxic signalling by the mitochondrial respiratory chain.
Hernansanz-Agustín P, Choya-Foces C, Carregal-Romero S, Ramos E, Oliva T, Villa-Piña T, Moreno L, Izquierdo-Álvarez A, Cabrera-García JD, Cortés A, Lechuga-Vieco AV, Jadiya P, Navarro E, Parada E, Palomino-Antolín A, Tello D, Acín-Pérez R, Rodríguez-Aguilera JC, Navas P, Cogolludo Á, López-Montero I, Martínez-Del-Pozo Á, Egea J, López MG, Elrod JW, Ruíz-Cabello J, Bogdanova A, Enríquez JA, Martínez-Ruiz A. Hernansanz-Agustín P, et al. Among authors: egea j. Nature. 2020 Oct;586(7828):287-291. doi: 10.1038/s41586-020-2551-y. Epub 2020 Jul 29. Nature. 2020. PMID: 32728214 Free PMC article.
Curcumin reduces renal damage associated with rhabdomyolysis by decreasing ferroptosis-mediated cell death.
Guerrero-Hue M, García-Caballero C, Palomino-Antolín A, Rubio-Navarro A, Vázquez-Carballo C, Herencia C, Martín-Sanchez D, Farré-Alins V, Egea J, Cannata P, Praga M, Ortiz A, Egido J, Sanz AB, Moreno JA. Guerrero-Hue M, et al. Among authors: egea j. FASEB J. 2019 Aug;33(8):8961-8975. doi: 10.1096/fj.201900077R. Epub 2019 Apr 29. FASEB J. 2019. PMID: 31034781
Editorial: New Insights Into Understanding and Managing NAFLD.
Escribano Ó, Francés DE, Otero YF, Egea J, González-Rodríguez Á. Escribano Ó, et al. Among authors: egea j. Front Med (Lausanne). 2021 Nov 12;8:777740. doi: 10.3389/fmed.2021.777740. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34869497 Free PMC article. No abstract available.
Protective Role of Nrf2 in Renal Disease.
Guerrero-Hue M, Rayego-Mateos S, Vázquez-Carballo C, Palomino-Antolín A, García-Caballero C, Opazo-Rios L, Morgado-Pascual JL, Herencia C, Mas S, Ortiz A, Rubio-Navarro A, Egea J, Villalba JM, Egido J, Moreno JA. Guerrero-Hue M, et al. Among authors: egea j. Antioxidants (Basel). 2020 Dec 31;10(1):39. doi: 10.3390/antiox10010039. Antioxidants (Basel). 2020. PMID: 33396350 Free PMC article. Review.
Toxicology of Blister Agents: Is Melatonin a Potential Therapeutic Option?
Romero A, Ramos E, López-Muñoz F, De Los Ríos C, Egea J, Gil-Martín E, Pita R, Torrado JJ, Serrano DR, Juberias A. Romero A, et al. Among authors: egea j. Diseases. 2021 Apr 10;9(2):27. doi: 10.3390/diseases9020027. Diseases. 2021. PMID: 33920224 Free PMC article. Review.
Targeting Nrf2 in Protection Against Renal Disease.
Guerrero-Hue M, Farre-Alins V, Palomino-Antolin A, Parada E, Rubio-Navarro A, Egido J, Egea J, Moreno JA. Guerrero-Hue M, et al. Among authors: egea j. Curr Med Chem. 2017;24(33):3583-3605. doi: 10.2174/0929867324666170511120814. Curr Med Chem. 2017. PMID: 28494744 Review.
Analogues of cannabinoids as multitarget drugs in the treatment of Alzheimer's disease.
Sánchez Montero JM, Agis-Torres A, Solano D, Söllhuber M, Fernandez M, Villaro W, Gómez-Cañas M, García-Arencibia M, Fernández-Ruiz J, Egea J, Martín MI, Girón R. Sánchez Montero JM, et al. Among authors: egea j. Eur J Pharmacol. 2021 Mar 15;895:173875. doi: 10.1016/j.ejphar.2021.173875. Epub 2021 Jan 15. Eur J Pharmacol. 2021. PMID: 33460612
Neuroprotective effects of E-PodoFavalin-15999 (Atremorine®).
Romero A, Parada E, González-Lafuente L, Farré-Alins V, Ramos E, Cacabelos R, Egea J. Romero A, et al. Among authors: egea j. CNS Neurosci Ther. 2017 May;23(5):450-452. doi: 10.1111/cns.12693. Epub 2017 Mar 30. CNS Neurosci Ther. 2017. PMID: 28371323 Free PMC article. No abstract available.
102 results